氨氯地平和缬沙坦联合治疗原发性高血压病住院患者的研究

目的 观察氨氯地平联合缬沙坦治疗血压在160～200／95～110mmHg的原发性高血压患者的有效性和耐受性。方法 156例血压在160～200／95～110mmHC原发性高血压病患者被随机分为氨氯地平缬沙坦联合治疗组和缬沙坦氢氯噻嗪治疗组，随访患者12个月。氨氯地平5mg ql，缬沙坦80mg qd作为氯氯地平缬沙坦联合治疗组的起初治疗，缬沙坦氢氯噻嗪联合治疗组起初治疗给予缬沙坦80mg qd，氢氯噻嗪25mg qd。如果出现低血压，氨氯地平、缬沙坦、氢氯噻嗪等剂量应当给予调整。结果 氨氯地平缬沙坦联合治疗组的舒张压和收缩压的控制率明显高于缬沙坦氢氯噻嗪联合治疗组。氨氯地平缬沙坦联合治疗组的平均住院日明显短于缬沙坦氢氯噻嗪联合治疗组。氨氯地平缬沙坦联合治疗组的副作用的发生几乎与缬沙坦氢氯噻嗪联合治疗组相当。结论 氨氯地平联合缬沙坦治疗血压在160～200／95～110mmHg的原发性高血压患者是有效的。氨氯地平联合缬沙坦治疗的耐受几乎与缬沙坦氢氯噻嗪联合治疗相当，但是由于氨氯地平联合缬沙坦治疗的有效性有助于治疗顺应性的提高。     

氨氯地平与氢氯噻嗪联用治疗老年高血压疗效观察

目的研究氨氯地平与氢氯噻嗪联用治疗老年轻、中度原发性高血压的疗效和安全性。方法73例轻、中度老年原发性高血压患者随机分成两组,治疗组服用氨氯地平2.5mg,1次/d;氢氯噻嗪12.5mg,1次/d;对照组单用氨氯地平2.5mg/d,两组均治疗4周。观察用药前后疗效及不良反应。结果治疗后两组血压均较治疗前显著下降(P<0.01)。氨氯地平联用氢氯噻嗪组总有效率为94.7%,单用氨氯地平组总有效率为76.3%,有显著性差异(P<0.05),药物相关不良反应治疗组显著低于对照组(2.8%vs16.2%,P<0.05)。结论氨氯地平与氢氯噻嗪联用疗效高、副作用少,且耐受性和安全性较好。     

缬沙坦联合氢氯噻嗪治疗老年原发性高血压的临床研究

目的 分析缬沙坦联合氢氯噻嗪治疗老年原发性高血压的临床疗效.方法 选择我院2019年1月至2020年8月收治的50例老年原发性高血压患者为研究对象,以随机数字表法将其分为观察组与对照组,各25例,对照组采取缬沙坦治疗,观察组采取缬沙坦联合氢氯噻嗪治疗,对比两组患者的治疗效果.结果 观察组患者治疗总有效率高于对照组,舒张压、收缩压水平低于对照组,不良反应发生率显著低于对照组,P＜0.05.结论 对老年原发性高血压患者应用缬沙坦联合氢氯噻嗪治疗可显著改善其病情,安全性较高.     

缬沙坦联合小剂量氢氯噻嗪治疗原发性高血压的疗效

目的 探讨缬沙坦联合小剂量氢氯噻嗪治疗原发性高血压的效果.方法 将72例原发性高血压患者按随机数字表法分为对照组和治疗组各36例,对照组采用缬沙坦80 mg口服,每日1次,晨起空服.治疗组在此基础上加用氢氯噻嗪12.5 mg口服,每日1次.疗程8周.观察2组降压效果及不良反应发生情况.结果 疗程结束后治疗组的降压效果明显优于对照组,2组总有效率相比差异有统计学意义(94.44% vs 80.56%,P<0.05).2组患者治疗期间,均无严重不良反应.结论 缬沙坦联合小剂量氢氯噻嗪治疗原发性高血压效果明显优于单用缬沙坦,且不良反应广.     

缬沙坦分别联合氢氯噻嗪与吲哒帕胺治疗中青年高血压比较

目的:比较缬沙坦分别联合氢氯噻嗪与吲哒帕胺治疗中青年高血压的临床疗效。方法:选取2014年2月~2016年2月在我院进行治疗的中青年高血压患者111例,按治疗方式不同分为三组,每组37例。对照组给予缬沙坦治疗,研究A组给予缬沙坦联合氢氯噻嗪治疗,研究B组给予缬沙坦联合吲哒帕胺治疗,比较三组患者临床疗效及治疗前后血压和心率的变化。结果:研究A组与研究B组患者临床效果明显高于对照组,差异具有统计学意义(P0.05);研究B组治疗总有效率较A组提高,差异具有统计学意义(P0.05);治疗前,三组患者收缩压、舒张压及心率无明显差异(P0.05),治疗后,三组患者收缩压、舒张压较明显改善,研究A组与研究B组改善效果较对照组更为显著,差异具有统计学意义(P0.05);治疗后三组患者心率无显著性差异(P0.05)。结论:缬沙坦分别联合氢氯噻嗪与吲哒帕胺均可明显改善患者高血压状态,且具有较高的安全性,且缬沙坦联合吲哒帕胺治疗效果更为显著,具有临床推广价值。     

替米沙坦、氢氯噻嗪、左旋氨氯地平小剂量联合治疗老年非杓型高血压的临床分析

目的:分析替米沙坦、氢氯噻嗪、左旋氨氯地平小剂量联合治疗老年非杓型高血压的临床疗效。方法:选取我院2016年1月~2017年4月收治的老年非杓型高血压患者74例,随机分为对照组和观察组各37例。对照组给予替米沙坦联合氢氯噻嗪治疗,观察组给予替米沙坦、、氢氯噻嗪、左旋氨氯地平小剂量联合治疗,比较两组治疗效果。结果:观察组治疗总有效率、血压昼夜节律达标率、动态血压达标率明显高于对照组,治疗后收缩压、舒张压、不良反应发生率均明显低于对照组(P0.05)。结论:替米沙坦、氢氯噻嗪、左旋氨氯地平小剂量联合方案可有效调节老年非杓型高血压的血压水平,治疗效果显著,用药安全性高,值得临床推广应用。     

缬沙坦联合氢氯噻嗪治疗原发性高血压的临床观察

将入选的280例原发性高血压患者随机分为A、B两组。两组在年龄、性别、病程及高血压分级等差异无统计意义。A组给予缬沙坦80mg口服,qd。B组在A组的基础上加用氢氯噻嗪12.5mg,qd口服。2组均用药8w。结果降压总效率A组86.4%,B组95.00%,2组差异有统计意义(P<0.05)。缬沙坦联合小剂量氢氯噻嗪治疗原发性高血压有较好效果。     

美托洛尔联合厄贝沙坦氢氯噻嗪对老年重症心力衰竭患者睡眠质量的影响

目的:探讨美托洛尔联合厄贝沙坦氢氯噻嗪对老年重症心力衰竭患者心功能和睡眠质量的影响。方法:选取2017年2月至2018年1月蚌埠市第三人民医院收治的老年重症心力衰竭患者94例,按照随机数字表法分为对照组和观察组,每组47例,对照组在常规治疗基础上给予美托洛尔片治疗,观察组在对照组基础上联合厄贝沙坦氢氯噻嗪片治疗,观察2组患者的临床疗效。结果:经治疗后,观察组患者有效率显著高于对照组(P0.05);观察组患者心功能改善程度明显优于对照组(P0.05);观察组患者睡眠质量评分明显高于对照组(P0.05);观察组患者不良反应发生率显著低于对照组(P0.05)。结论:美托洛尔联合厄贝沙坦氢氯噻嗪治疗老年重症心力衰竭能够提高临床疗效,促进患者心功能恢复,降低不良反应发生率,改善其睡眠质量,值得临床推广。     

培哚普利和苯磺酸氨氯地平联合应用对高血压蛋白尿的作用

目的 观察培哚普利和苯磺酸氨氯地平联合应用治疗高血压蛋白尿的临床疗效.方法 将136例高血压合并肾脏损害蛋白尿的患者随机分为A、B两组,A组给予培哚普利4 mg/d和苯磺酸氨氯地平5 mg/d,B组给予苯磺酸氨氯地平5 mg/d和氢氯噻嗪12.5 mg/d,均治疗26周.两组治疗前及治疗后测血压、尿白蛋白、尿素氮(BUN)、血肌酐(Scr),并计算肌酐清除率(Ccr)和不良反应.结果 两组治疗后6.5个月,血压较前明显下降(P＜0.01),两组下降值比较差异无统计学意义(P＞0.05).两组治疗后尿蛋白均下降(P＜0.05),A组降低尿蛋白作用比B组更显著(P＜0.01).A组降低Scr、BUN更显著(P＜0.05).结论 培哚普利和氨氯地平联合应用能明显较平稳降低高血压,显著减少尿蛋白,有效保护肾功能.     

氨氯地平联合缬沙坦对原发性高血压患者的疗效

目的观察氨氯地平联合缬沙坦治疗原发性高血压的疗效。方法 184例原发性高血压患者根据治疗药物不同随机分为3组,A组采用氨氯地平联合缬沙坦治疗(n=90),B组单用氨氯地平治疗(n=44),C组单用缬沙坦治疗(n=50),比较3组降压效果与不良反应情况。结果 A、B、C组总有效率分别为95.6%(86/90)、59.1%(26/44)和68.0%(34/50);A组总有效率高于B组与C组(P均<0.05),而B、C2组总有效率比较差异无统计学意义(P>0.05)。A、B、C组不良反应发生率分别为11.1%(10/90)、13.6%(6/44)和12.0%(6/50),3组比较,差异无统计学意义(P>0.05)。结论氨氯地平联合缬沙坦治疗原发性高血压疗效优于单独用药。     

Effect of 5-fluorouracil, mitoxantrone, methotrexate, and vincristine on the antibacterial activity of ceftriaxone, ceftazidime, cefotiam, piperacillin, and netilmicin

Using the checkerboard agar dilution technique, antibacterial activity and in vitro interactions of 4 antineoplastic agents and 5 antimicrobial drugs were examined against 56 strains of 7 bacterial species. 5-fluorouracil was found to inhibit all strains of Staphylococcus aureus and of Staphylococcus epidermidis at a concentration of 0.8 micrograms/ml or less. 84% of all gram-negative strains were inhibited synergistically when 5-fluorouracil was combined with beta-lactam antibiotics. Methotrexate and cefotiam were antagonistic in 42% of all combinations, especially when tested against Escherichia coli and Klebsiella pneumoniae.     

Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Agar dilution MICs of 10 agents against 410 non-Pseudomonas aeruginosa gram-negative nonfermentative rods were determined. MICs at which 50 and 90% of the isolates were inhibited, respectively, were as follows (in micrograms per milliliter): sparfloxacin, 0.5 and 8.0; levofloxacin, 1.0 and 8.0; ciprofloxacin, 2.0 and 32.0; ofloxacin, 2.0 and 32.0; D-ofloxacin, 32.0 and > 64.0; ceftazidime, 8.0 and 64.0; piperacillin with or without tazobactam, 16.0 and > 64.0; trimethoprim-sulfamethoxazole, 0.5 and > 64.0; imipenem, 2.0 and > 64.0. With the exception of those for Stenotrophomonas maltophilia, Burkholderia cepacia, and Alcaligenes faecalis-A. odorans, agar dilution MICs for all strains tested were within 1 dilution of inhibitory (bacteriostatic) levels as determined by time-kill methodology.     

Comparative ototoxicity of ribostamycin, dactimicin, dibekacin, kanamycin, amikacin, tobramycin, gentamicin, sisomicin and netilmicin in the inner ear of guinea pigs

Nine aminoglycoside antibiotics, ribostamycin (RSM), dactimicin (DAC), dibekacin (DKB), kanamycin (KM), amikacin (AMK), netilmicin (NTL), tobramycin (TOB), gentamicin (GM) and sisomicin (SISO) were administered intramuscularly to guinea pigs for 4 weeks, and ototoxicity and drug concentration in the inner ear fluid were determined. RSM and DAC showed the weakest ototoxicity against the cochlea and vestibular organs. AMK and KM were more toxic to cochlea than vestibular organs. DKB, TOM, GM and SISO were equally toxic to vestibular organs and cochlea. NTL was more toxic to vestibular organs than cochlea. As judged from the pinna reflex response and hair cell damage in the cochlea, the order of auditory toxicity was the following: SISO greater than GM greater than TOB greater than AMK greater than DKB greater than KM greater than NTL, DAC RSM, whereas the vestibular toxicity was in the following order: SISO greater than GM greater than DKB greater than TOB greater than NTL greater than AMK greater than KM greater than DAC, RSM. RSM, causing the weakest ototoxicity, showed a low drug concentration in the inner ear fluid, while GM, causing severe ototoxicity, showed the highest drug level under the same conditions.     

Reviews of books, videos, CDs, audiotapes, web sites, and more, written by emergency nurses

Zimmermann PG. Philadelphia: Hanley & Belfus, 2002, 243 pp, ISBN 1-56053-529-6.